OncLive Staff

Vote on the top abstracts and topics to watch in gynecologic and gastrointestinal oncology during the 2025 ESMO Congress.

The top 5 OncLive TV videos of the week cover insights in lung cancer, and prostate cancer, myelofibrosis.

The FDA clears maintenance lurbinectedin combination in lung cancer, T-DxD sBLA in HER2-positive breast cancer is accepted for review, and more.

Here is your guide to all therapeutic options that were approved by the FDA in September 2025 spanning tumor types.

The top 5 OncLive TV videos of the week cover insights in solid tumors, breast cancer, pancreatic cancer, and multiple myeloma.

Imlunestrant joins the treatment arsenal for ESR1-mutated metastatic breast cancer, T-DXd doublet gets priority review in HER2+ breast cancer, and more.

Vote in OncLive's polls to share which lung and genitournary cancer abstracts you're most anticipating at the 2025 ESMO Congress.

The top 5 OncLive TV videos of the week cover insights in lung cancer, multiple myeloma, and ovarian cancer.

The FDA held a Type A meeting for RP1 in advanced melanoma, the AACR released its Annual Cancer Progress Report, and more.

The top 5 OncLive TV videos of the week cover insights in lung cancer, non–muscle-invasive bladder cancer, and colorectal cancer.

The FDA has approved TAR-200 in urothelial cancer and selumetinib in pediatric NF-1–associated inoperable plexiform neurofibromas, and more.

The top 5 OncLive videos of the week cover insights in sarcoma, colorectal cancer, acute lymphoblastic leukemia, renal cell carcinoma.

FDA grants type A meeting to discuss RP1 BLA in melanoma, CBP/p300 bromodomain inhibitor gets fast track status in NSCLC, and more.

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

The top 5 OncLive videos of the week cover insights in lung cancer, ovarian cancer, breast cancer, and prostate cancer.

The FDA has cleared a 3-month subcutaneous depot formulation of leuprolide mesylate in prostate cancer, gedatolisib NDA is under review in breast cancer, and more.

The top 5 OncLive videos of the week cover insights in polycythemia vera, multiple myeloma, colorectal cancer, LBCL, and mantle cell lymphoma.

Adjuvant atezolizumab boosts survival in bladder cancer, FDA clears companion diagnostic for nivolumab doublet in MSI-H/dMMR colorectal cancer, and more.

The top 5 OncLive videos of the week cover insights in MCL, prostate cancer, plexiform neurofibromas, breast cancer, and follicular lymphoma.

Vepdegestrant NDA under FDA review in ESR1-mutated breast cancer, Oncomine Dx Target Test gets greenlit as zongertinib companion diagnostic in NSCLC.

The top 5 OncLive videos of the week cover insights in renal cell carcinoma, glioma, multiple myeloma, and ovarian cancer.

The FDA grants accelerated approval to zongertinib in lung cancer, clears dordaviprone in glioma, and awards priority review to liso-cel sBLA in MZL.

The top 5 OncLive videos of the week cover insights in lung cancer, myelofibrosis, and mantle cell lymphoma.

Perioperative durvalumab sBLA gets priority review in gastric/GEJ cancer, acalabrutinib combination sNDA under review in CLL, and more.

Here is your guide to all therapeutic options that were approved by the FDA in July 2025 spanning tumor types.

The top 5 OncLive videos of the week cover insights in multiple myeloma, breast cancer, melanoma, and CLL/SLL.

RP1 BLA in advanced melanoma receives CRL from FDA, generic ibrutinib tablets gets green light for B-cell malignancies, and more.

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

Glofitamab received a CRL from the FDA in R/R DLBCL, ODAC voted against belantamab mafodotin in R/R multiple myeloma, and more.